|

Nigeria Receives Over 1 Million Meningitis Vaccine Doses

The Federal Ministry of Health has received over one million doses of the pentavalent meningococcal conjugate vaccine (Men5CV) from Gavi’s...

The Federal Ministry of Health has received over one million doses of the pentavalent meningococcal conjugate vaccine (Men5CV) from Gavi’s global stockpile to address the meningitis outbreak in northern Nigeria.

In a joint statement released by Gavi, the World Health Organization (WHO), and UNICEF on April 5, 2025, it was revealed that the vaccine will be used in a targeted outbreak response campaign for individuals aged 1 to 29, the most affected demographic.

The first phase of the campaign will begin in Kebbi and Sokoto states, with plans to expand to Yobe State as more vaccine doses arrive.

“This arrival of the Men5CV vaccines is a crucial milestone in Nigeria’s fight against the meningitis outbreak,” said Prof. Muhammad Pate, Coordinating Minister of Health and Social Welfare.

“It reflects our commitment under President Bola Ahmed Tinubu’s Renewed Hope Agenda to protect the health of all Nigerians—especially our children and young people.”

As of March 26, 2025, Nigeria has recorded 807 suspected cases of cerebrospinal meningitis and 74 deaths across 22 states, with a case fatality rate of 9.2%.

UNICEF Representative in Nigeria, Cristian Munduate, emphasized the importance of the vaccine: “Every child deserves protection from life-threatening diseases like meningitis, and this vaccine marks a critical step in stopping the outbreak and safeguarding Nigeria’s most vulnerable populations.”

WHO Country Representative, Dr. Walter Mulombo, also underscored the long-term significance of the vaccine in preventing future outbreaks. “This collaborative effort between the Nigerian government, WHO, Gavi, and partners is key to strengthening Nigeria’s health security,” he said.

The Men5CV vaccine is a key element in both controlling the current outbreak and preventing future ones in Nigeria.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign up for the HB Newsletter

Get stories that matter delivered directly to your inbox

OTHER STORIES

Get the stories that matter most delivered directly to your inbox

© Copyright 2025 – HB Report. All Rights Reserved

HB Logo

Sign up for the HB newsletter

By signing up, you agree to our Privacy Policy and Terms of Use, and agree to receive content that may sometimes include advertisements. You may opt out at any time.